Cytarabine/daunorubicin Reactions 1680, p105 - 2 Dec 2017 Optic neuropathy and bull’s eye maculopathy: case report A 50-year-old man developed optic neuropathy and bull’s eye maculopathy during treatment with cytarabine and daunorubicin [dosages not stated]. The man, who had a history of acute myeloid leukaemia, received treatment with IV cytarabine and daunorubicin. After three cycles of cytarabine and daunorubicin, he experienced an abrupt decrease in vision in his left eye. The man started receiving treatment with prednisolone. Later, the treatment was discontinued. Six weeks after the appearance of symptoms, his best corrected visual acuity was 20/20 in the right eye and 20/30 in the left eye. Colour vision was defective in both the eyes. A relative afferent pupillary defect was noted in his left eye. There was pallor of both the optic discs with a cup-to-disc ratio of 0.3. An early ’bull’s eye’ pattern was noted in both the eyes. Automated perimetry showed peripheral depressed points in the right eye and constriction of the visual field in the left eye with a small temporal island of vision. Optical coherence tomography (OCT) demonstrated thinning of the retinal nerve fibre layer in both the eyes. The OCT of the macula revealed thinning and alteration of the foveal contour in both the eyes. Fundus fluorescein angiography showed window defects with mottled hyper fluorescence in the para foveal region in both the eyes. Disc staining was observed in both the eyes. He was diagnosed with chemotherapy induced optic neuropathy with maculopathy [durations of treatments to reactions onset not stated]. He received different chemotherapy treatment secondary to bone marrow transplantation. At follow-up, he showed no worsening of vision or progression of optic nerve and macular changes. Author comment: "We report a case of Presumed Chemotherapy-Induced optic neuropathy and maculopathy secondary to treatment with cytarabine and daunorubicin for Acute Myeloid Leukaemia (AML)." Mathew DJ, et al. Presumed chemotherapy-induced optic neuropathy and maculopathy: A case report. Open Ophthalmology Journal 11: 298-304, Sep 2017. Available from: URL: - India 803285172 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial